186 related articles for article (PubMed ID: 3126294)
1. One-month release injectable microcapsules of a luteinizing hormone-releasing hormone agonist (leuprolide acetate) for treating experimental endometriosis in rats.
Okada H; Heya T; Ogawa Y; Shimamoto T
J Pharmacol Exp Ther; 1988 Feb; 244(2):744-50. PubMed ID: 3126294
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic hypogonadism induced by a delayed-release preparation of microcapsules of D-Trp-6-luteinizing hormone-releasing hormone: a preliminary study in eight women with endometriosis.
Zorn JR; Tanger C; Roger M; Grenier J; Comaru-Schally AM; Schally AV
Int J Fertil; 1986; 31(1):11-3, 16-27. PubMed ID: 2908272
[TBL] [Abstract][Full Text] [Related]
3. Regression of rat mammary tumors by a potent luteinizing hormone-releasing hormone analogue (leuprolide) administered vaginally.
Okada H; Sakura Y; Kawaji H; Yashiki T; Mima H
Cancer Res; 1983 Apr; 43(4):1869-74. PubMed ID: 6403230
[TBL] [Abstract][Full Text] [Related]
4. Development of radioimmunoassay for a potent luteinizing hormone-releasing hormone antagonist. Evaluation of serum levels after injection of [Ac-3-(2-naphthyl)-D-Ala1, D-Phe(pCl)2, 3-(3-pyridyl)-D-Ala3, D-Cit6, D-Ala10] LHRH.
Csernus VJ; Szende B; Groot K; Redding TW; Schally AV
Arzneimittelforschung; 1990 Feb; 40(2 Pt 1):111-8. PubMed ID: 2110458
[TBL] [Abstract][Full Text] [Related]
5. Formulation study of leuprorelin acetate to improve clinical performance.
Toguchi H
Clin Ther; 1992; 14 Suppl A():121-30. PubMed ID: 1606592
[TBL] [Abstract][Full Text] [Related]
6. [Studies on endocrine therapy of endometriosis].
Terakawa N
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Aug; 41(8):981-9; discussion 1000-7. PubMed ID: 2530291
[TBL] [Abstract][Full Text] [Related]
7. [Conservative surgery combined with depot medroxyprogesterone acetate in treatment of moderate or severe endometriosis].
Zhou J; Lei ZW; Lü JQ; Sun J; Xu XW
Zhonghua Fu Chan Ke Za Zhi; 2005 Jan; 40(1):5-8. PubMed ID: 15774083
[TBL] [Abstract][Full Text] [Related]
8. [Once-a-month injectable microcapsules of leuprorelin acetate].
Toguchi H; Ogawa Y; Okada H; Yamamoto M
Yakugaku Zasshi; 1991 Aug; 111(8):397-409. PubMed ID: 1795229
[TBL] [Abstract][Full Text] [Related]
9. Treatment of endometriosis with a long-acting gonadotropin-releasing hormone agonist plus medroxyprogesterone acetate.
Cedars MI; Lu JK; Meldrum DR; Judd HL
Obstet Gynecol; 1990 Apr; 75(4):641-5. PubMed ID: 2138265
[TBL] [Abstract][Full Text] [Related]
10. Leuprolide acetate for the treatment of endometriosis.
Miller JD
Prog Clin Biol Res; 1990; 323():337-41. PubMed ID: 2106145
[No Abstract] [Full Text] [Related]
11. A new animal model for evaluation of long-term growth rate over one month by rhGH/PLGA microcapsule formulations.
Takada S; Kurokawa T; Misaki M; Taira K; Yamagata Y
J Pharm Pharmacol; 2003 Jul; 55(7):951-61. PubMed ID: 12906752
[TBL] [Abstract][Full Text] [Related]
12. Medical reversible castration with D-Trp-6-LH-RH microcapsules for the treatment of endometriosis. Preliminary results in a series of 51 patients.
Zorn JR; Soubrane O; Siboni O; Papageorgiou G
Contrib Gynecol Obstet; 1987; 16():254-9. PubMed ID: 2961507
[No Abstract] [Full Text] [Related]
13. [Treatment of prostatic cancer with slow-release formulation of luteinizing hormone releasing hormone (LH-RH) analog].
Fuse H; Akimoto S; Akakura K; Shimazaki J; Murakami S
Hinyokika Kiyo; 1988 Mar; 34(3):555-60. PubMed ID: 3133936
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of endometriosis with domestic luteinizing hormone--releasing hormone analogue].
Geng L; Gu FY; Zhang LZ
Zhonghua Fu Chan Ke Za Zhi; 1994 Oct; 29(10):592-4, 636. PubMed ID: 7712871
[TBL] [Abstract][Full Text] [Related]
15. Pituitary desensitization for eight weeks after the administration of two distinct gonadotrophin-releasing hormone agonists.
Matteo M; Caroppo E; Gliozheni O; Carone D; Schonauer LM; Vizziello G; Greco P; D'Amato G
Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):77-80. PubMed ID: 16359772
[TBL] [Abstract][Full Text] [Related]
16. Treatment of endometriosis with a delayed release preparation of the agonist D-Trp6-luteinizing hormone-releasing hormone: long-term follow-up in a series of 50 patients.
Zorn JR; Mathieson J; Risquez F; Comaru-Schally AM; Schally AV
Fertil Steril; 1990 Mar; 53(3):401-6. PubMed ID: 2137792
[TBL] [Abstract][Full Text] [Related]
17. Nafarelin controlled release injectable: theoretical clinical plasma profiles from multiple dosing and from mixtures of microspheres containing 2 per cent, 4 per cent and 7 per cent nafarelin.
Burns RA; Vitale K; Sanders LM
J Microencapsul; 1990; 7(3):397-413. PubMed ID: 2143531
[TBL] [Abstract][Full Text] [Related]
18. Controlled release of LHRH agonist, leuprolide acetate, from microcapsules: serum drug level profiles and pharmacological effects in animals.
Ogawa Y; Okada H; Heya T; Shimamoto T
J Pharm Pharmacol; 1989 Jul; 41(7):439-44. PubMed ID: 2570847
[TBL] [Abstract][Full Text] [Related]
19. Effects of danazol, gonadotropin-releasing hormone agonist, and a combination of danazol and gonadotropin-releasing hormone agonist on experimental endometriosis.
Sakata M; Terakawa N; Mizutani T; Tanizawa O; Matsumoto K; Terada N; Sudo K
Am J Obstet Gynecol; 1990 Nov; 163(5 Pt 1):1679-84. PubMed ID: 2122726
[TBL] [Abstract][Full Text] [Related]
20. Effects of TAP-144-SR, a sustained-release formulation of a potent GnRH agonist, on experimental endometriosis in the rat.
Sudo K; Shiota K; Masaki T; Fujita T
Endocrinol Jpn; 1991 Feb; 38(1):39-45. PubMed ID: 1915112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
